β受体阻滞剂预防心律失常和心肌缺血：来自心脏心律失常抑制试验（CAST）、加拿大胺碘酮心肌梗死心律失常试验（CAMIAT）及欧洲心肌梗死胺碘酮试验（EMIAT）的线索。心脏心律失常抑制试验。加拿大胺碘酮心肌梗死心律失常试验。欧洲心肌梗死胺碘酮试验。 - Suppr

Suppr

超能文献

Beta-blocker prevention of proarrhythmia and proischemia: clues from CAST, CAMIAT, and EMIAT. Cardiac Arrhythmia Suppression Trial. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. European Myocardial Infarct Amiodarone Trial.

作者信息

Kennedy H L

出版信息

Am J Cardiol. 1997 Nov 1;80(9):1208-11. doi: 10.1016/s0002-9149(97)00675-9.

DOI:10.1016/s0002-9149(97)00675-9

PMID:9359552

Abstract

摘要

相似文献

Beta-blocker prevention of proarrhythmia and proischemia: clues from CAST, CAMIAT, and EMIAT. Cardiac Arrhythmia Suppression Trial. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. European Myocardial Infarct Amiodarone Trial.β受体阻滞剂预防心律失常和心肌缺血：来自心脏心律失常抑制试验（CAST）、加拿大胺碘酮心肌梗死心律失常试验（CAMIAT）及欧洲心肌梗死胺碘酮试验（EMIAT）的线索。心脏心律失常抑制试验。加拿大胺碘酮心肌梗死心律失常试验。欧洲心肌梗死胺碘酮试验。

Am J Cardiol. 1997 Nov 1;80(9):1208-11. doi: 10.1016/s0002-9149(97)00675-9.

Amiodarone in high-risk post-infarction patients, Lessons from EMIAT and CAMIAT. European Myocardial Infarct Amiodarone Trial and Canadian Amiodarone Myocardial Infarction Arrhythmia Trial.胺碘酮用于心肌梗死后高危患者：EMIAT和CAMIAT研究的经验教训。欧洲心肌梗死胺碘酮试验和加拿大胺碘酮心肌梗死心律失常试验

Indian Heart J. 1996 Jul-Aug;48(4):339-41.

Amiodarone interaction with beta-blockers: analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators.胺碘酮与β受体阻滞剂的相互作用：合并的EMIAT（欧洲心肌梗死胺碘酮试验）和CAMIAT（加拿大胺碘酮心肌梗死试验）数据库分析。EMIAT和CAMIAT研究人员。

Circulation. 1999 May 4;99(17):2268-75. doi: 10.1161/01.cir.99.17.2268.

Role of antiarrhythmic agents after myocardial infarction with special reference to the EMIAT and CAMIAT trials of amiodarone. European Myocardial Infarct Amiodarone Trial. Canadian Amiodarone Myocardial Infarction Trial.心肌梗死后抗心律失常药物的作用，特别提及胺碘酮的欧洲心肌梗死胺碘酮试验（EMIAT）和加拿大胺碘酮心肌梗死试验（CAMIAT）。欧洲心肌梗死胺碘酮试验。加拿大胺碘酮心肌梗死试验。

Prog Cardiovasc Dis. 1998 Jul-Aug;41(1):65-70. doi: 10.1016/s0033-0620(98)80023-6.

Identification of post acute myocardial infarction patients with potential benefit from prophylactic treatment with amiodarone. A substudy of EMIAT (the European Myocardial Infarct Amiodarone Trial).识别可能从胺碘酮预防性治疗中获益的急性心肌梗死后患者。EMIAT（欧洲心肌梗死胺碘酮试验）的一项子研究。

Eur Heart J. 1998 Jan;19(1):85-95. doi: 10.1053/euhj.1997.0823.

Lessons from antiarrhythmic trials involving class III antiarrhythmic drugs.来自涉及III类抗心律失常药物的抗心律失常试验的经验教训。

Am J Cardiol. 1999 Nov 4;84(9A):83R-89R. doi: 10.1016/s0002-9149(99)00707-9.

From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.从一流到三流：抗心律失常治疗的近期变革——来自临床试验的经验教训

Am J Cardiol. 1996 Aug 29;78(4A):28-33. doi: 10.1016/s0002-9149(96)00450-x.

Amiodarone after myocardial infarction: EMIAT and CAMIAT trials.心肌梗死后的胺碘酮：EMIAT和CAMIAT试验

Lancet. 1997 Jun 14;349(9067):1767-8. doi: 10.1016/S0140-6736(05)62982-0.

Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators.频发或反复室性早搏患者心肌梗死后转归的随机试验：CAMIAT。加拿大胺碘酮心肌梗死心律失常试验研究者。

Lancet. 1997 Mar 8;349(9053):675-82. doi: 10.1016/s0140-6736(96)08171-8.

What have clinical trials taught us about proarrhythmia?关于致心律失常作用，临床试验告诉了我们什么？

Can J Cardiol. 1996 Apr;12 Suppl B:20B-26B.

引用本文的文献

Review of nifedipine GITS in the treatment of high risk patients with coronary artery disease and hypertension.硝苯地平控释片治疗冠心病合并高血压高危患者的综述。

Vasc Health Risk Manag. 2009;5(1):429-40. doi: 10.2147/vhrm.s3066.

[Perioperative cardioprotection. Golden standard beta-blockade?].[围手术期心脏保护。黄金标准β受体阻滞剂？]

Anaesthesist. 2007 Mar;56(3):285-96; quiz 297-8. doi: 10.1007/s00101-007-1144-6.

Optimising the use of beta-adrenoceptor antagonists in coronary artery disease.优化β-肾上腺素能受体拮抗剂在冠状动脉疾病中的应用。

Drugs. 2005;65(6):787-97. doi: 10.2165/00003495-200565060-00006.

Prevention of and medical therapy for atrial arrhythmias in heart failure.心力衰竭中心房性心律失常的预防与药物治疗

Heart Fail Rev. 2002 Jul;7(3):267-83. doi: 10.1023/a:1020097728178.

Can antiarrhythmic agents be selected based on mechanism of action?抗心律失常药物能否根据作用机制来选择？

Drugs. 2000 Dec;60(6):1315-28. doi: 10.2165/00003495-200060060-00006.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验